TECH Stock Performance, Insider Transaction and News

TECH - Bio-Techne Corp

Market Cap	12.91B	P/E	48.82	EPS this Y	-11.10%	Ern Qtrly Grth	-45.10%
Income	224.11M	Forward P/E	34.17	EPS next Y	15.30%	50D Avg Chg	1.00%
Sales	1.14B	PEG	6.32	EPS past 5Y	14.55%	200D Avg Chg	3.00%
Dividend	N/A	Price/Book	6.83	EPS next 5Y	5.56%	52W High Chg	-16.00%
Recommedations	1.70	Quick Ratio	2.54	Shares Outstanding	157.19M	52W Low Chg	21.00%
Insider Own	0.97%	ROA	6.32%	Shares Float	155.39M	Beta	1.22
Inst Own	100.52%	ROE	11.83%	Shares Shorted/Prior	5.32M/4.58M	Price	82.02
Gross Margin	67.26%	Profit Margin	19.58%	Avg. Volume	914,012	Target Price	80.55
Oper. Margin	18.39%	Earnings Date	May 1	Volume	1,280,237	Change	-0.10%

Healthcare | Biotechnology | United States

About Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Bio-Techne Corp News

04/10/24	BIO-TECHNE TO HOST CONFERENCE CALL ON MAY 1, 2024, TO ANNOUNCE THIRD QUARTER FISCAL 2024 FINANCIAL RESULTS
04/08/24	BIO-TECHNE SURPASSES 10,000 PEER-REVIEWED PUBLICATIONS CITING RNAscope TECHNOLOGY
04/03/24	BIO-TECHNE TO PRESENT AT THE 2024 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) CONFERENCE
04/01/24	BIO-TECHNE RECEIVES CiteAb'S ELISA KIT SUPPLIER OF THE YEAR AND SPATIAL BIOLOGY INNOVATION AWARDS
04/01/24	Bio-Techne (NASDAQ:TECH) shareholders have earned a 7.4% CAGR over the last five years
03/28/24	BIO-TECHNE AND NIKON INSTRUMENTS INC. ANNOUNCE PARTNERSHIP TO EXPAND ACCESS TO INNOVATIVE SPATIAL BIOLOGY SERVICES
03/28/24	3 Biotech Stocks That Could Be Multibaggers in the Making: March Edition
03/22/24	BIO-TECHNE RECEIVES EUROPEAN IVDR CERTIFICATION FOR DIAGNOSTIC TEST TO MONITOR CHRONIC MYELOID LEUKEMIA
03/18/24	7 Biotech Stocks Ready to Ride the Sector’s Resurgence
03/17/24	30 Biggest Biotechnology Companies in the World
03/12/24	BIO-TECHNE TO PRESENT AT THE KEYBANC LIFE SCIENCES & MEDTECH INVESTOR FORUM
03/11/24	Director Roeland Nusse Sells 10,400 Shares of Bio-Techne Corp (TECH)
03/06/24	BIO-TECHNE TO PRESENT AT THE BARCLAYS 26th ANNUAL GLOBAL HEALTHCARE CONFERENCE
03/02/24	What Does Bio-Techne Corporation's (NASDAQ:TECH) Share Price Indicate?
06:15 AM	What Makes Bio-Techne Corporation (TECH) an Investment Bet?
02/13/24	The 3 Best Biotech Stocks to Buy in February 2024
02/04/24	Bio-Techne Corporation Just Missed EPS By 36%: Here's What Analysts Think Will Happen Next
02/02/24	Bio-Techne Corporation (NASDAQ:TECH) Q2 2024 Earnings Call Transcript
02/02/24	Q2 2024 Bio-Techne Corp Earnings Call
02/01/24	Bio-Techne Corp (TECH) Reports Mixed Q2 Fiscal 2024 Results Amid Industry Headwinds

TECH Chatroom

Stock_Titan Posted - 1 week ago

$TECH BIO-TECHNE TO HOST CONFERENCE CALL ON MAY 1, 2024, TO ANNOUNCE THIRD QUARTER FISCAL 2024 FINANCIAL RESULTS https://www.stocktitan.net/news/TECH/bio-techne-to-host-conference-call-on-may-1-2024-to-announce-third-quns1saxdgve.html

Stock_Titan Posted - 2 weeks ago

$TECH BIO-TECHNE SURPASSES 10,000 PEER-REVIEWED PUBLICATIONS CITING RNAscope TECHNOLOGY https://www.stocktitan.net/news/TECH/bio-techne-surpasses-10-000-peer-reviewed-publications-citing-rn-tdapgpo6gymd.html

Stock_Titan Posted - 2 weeks ago

$TECH BIO-TECHNE TO PRESENT AT THE 2024 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) CONFERENCE https://www.stocktitan.net/news/TECH/bio-techne-to-present-at-the-2024-american-association-for-cancer-rzjehuzrwd0v.html

Stock_Titan Posted - 3 weeks ago

$TECH BIO-TECHNE RECEIVES CiteAb'S ELISA KIT SUPPLIER OF THE YEAR AND SPATIAL BIOLOGY INNOVATION AWARDS https://www.stocktitan.net/news/TECH/bio-techne-receives-cite-ab-s-elisa-kit-supplier-of-the-year-and-bg74mkn7l33f.html

Stock_Titan Posted - 03/28/24

$TECH BIO-TECHNE AND NIKON INSTRUMENTS INC. ANNOUNCE PARTNERSHIP TO EXPAND ACCESS TO INNOVATIVE SPATIAL BIOLOGY SERVICES https://www.stocktitan.net/news/TECH/bio-techne-and-nikon-instruments-inc-announce-partnership-to-expand-kmetqz0a1zfy.html

DonCorleone77 Posted - 1 month ago

$TECH Bio-Techne receives European IVDR certification for diagnostic test Bio-Techne announced that Asuragen, part of Bio-Techne's Molecular Diagnostics Division, has completed the Class C Certification under the new European Union In Vitro Diagnostic Regulation for its QuantideX qPCR BCR-ABL IS Kit. Previously, the kit was CE-IVD marked for sale in the EU in compliance with the In Vitro Diagnostic Directive, which has now been replaced by the IVDR. The QuantideX qPCR BCR-ABL IS Kit gives labs a robust and reliable tool for monitoring chronic myeloid leukemia patients.

Stock_Titan Posted - 1 month ago

$TECH BIO-TECHNE RECEIVES EUROPEAN IVDR CERTIFICATION FOR DIAGNOSTIC TEST TO MONITOR CHRONIC MYELOID LEUKEMIA https://www.stocktitan.net/news/TECH/bio-techne-receives-european-ivdr-certification-for-diagnostic-test-aiz8o88hqoae.html

EmmaRespond Posted - 1 month ago

Investing in the Future of Bio-Techne Corporation: Why You Should Buy $TECH Stock http://dlvr.it/T4Q488

JackDarwin Posted - 1 month ago

$TECH Bullish Engulfing Formed At Downtrend With High Volume.

Stock_Titan Posted - 1 month ago

$TECH BIO-TECHNE TO PRESENT AT THE KEYBANC LIFE SCIENCES & MEDTECH INVESTOR FORUM https://www.stocktitan.net/news/TECH/bio-techne-to-present-at-the-keybanc-life-sciences-amp-medtech-iuif3spz5j0g.html

insiderbuyingselling Posted - 1 month ago

$TECH new insider selling: 10400 shares. http://insiderbuyingselling.com/?t=TECH

Stock_Titan Posted - 1 month ago

$TECH BIO-TECHNE TO PRESENT AT THE BARCLAYS 26th ANNUAL GLOBAL HEALTHCARE CONFERENCE https://www.stocktitan.net/news/TECH/bio-techne-to-present-at-the-barclays-26th-annual-global-healthcare-umt8xzb0ur0g.html

Official_Petrafreddi Posted - 2 months ago

$TECH up 👆 +8.05% YTD and +12.31% from Jan lows outperforming both the S&P 500 and Nasdaq-100 Great little ETF that selects high-growth relatively cheap tech stocks Top 3 Holdings: $UBER $CRM $NXPI

win_condition Posted - 2 months ago

@symptl I am inexperienced with mergers and acquisition but couldn't $TECH do a hostile take-over $NSTGQ for its R&D now that $NSTGQ market cap is in the millions?

win_condition Posted - 2 months ago

did $NSTGQ and $TXG waste resources battling it out in the legal realm and now $TECH is going to reign supreme? Was there any grounds for the legal dispute??? did their technology really overlap?

win_condition Posted - 2 months ago

$TXG does research based on their platform lead to any new therapies? who is the best here? $NSTGQ $TECH

Thestocktraderhubzee Posted - 2 months ago

WATCHLIST FEB 05 2024.. $HLI UBS Maintains Buy on Houlihan Lokey, Raises Price Target to $142 $EMN UBS Maintains Neutral on Eastman Chemical, Raises Price Target to $93 $AMZN UBS Maintains Buy on Amazon.com, Raises Price Target to $198 $TECH Bio-Techne shares are trading lower after Stifel downgraded the stock from Buy to Hold and announced a $65 price target. $WRK RBC Capital Reiterates Sector Perform on WestRock, Maintains $42 Price Target

Thestocktraderhubzee Posted - 2 months ago

$TECH Bio-Techne shares are trading lower after Stifel downgraded the stock from Buy to Hold and announced a $65 price target.

Yaloo159 Posted - 2 months ago

$TECH

epsguid Posted - 2 months ago

$TECH reported earnings of $0.33, consensus was $0.36 via @eWhispers #epsmiss http://eps.sh/d/tech

DonCorleone77 Posted - 2 months ago

$TECH Bio-Techne reports Q2 adjusted EPS 40c, consensus 41c Reports Q2 revenue $272.6M, consensus $277.53M. "I am pleased with the team's continued execution in this dynamic operating environment, as we navigated a challenging China landscape and conservatism from a subset of biotech customers, which was partially offset by continued strength in our academic end market," said Kim Kelderman, president and CEO of Bio-Techne. "Encouragingly, we are seeing initial signs of stabilization in China, and remain confident in the long-term high-growth potential of this geography."

DonCorleone77 Posted - 01/31/24

$MRK $HON $MO $TSCO $TECH Notable companies reporting before tomorrow's open Notable companies reporting before tomorrow's open, with earnings consensus, include Merck (MRK), consensus (11c)... Honeywell (HON), consensus $2.59... Altria Group (MO), consensus $1.17... Becton Dickinson (BDX), consensus $2.40... Royal Caribbean (RCL), consensus $1.13... Cardinal Health (CAH), consensus $1.60... Tractor Supply (TSCO), consensus $2.22... Sirius XM (SIRI), consensus 8c... Stanley Black & Decker (SWK), consensus 79c... Quest Diagnostics (DGX), consensus $2.11... Bio-Techne (TECH), consensus 41c... Peloton (PTON), consensus (53c).

EarningsInsider Posted - 01/27/24

Bio-Techne Sees Short Interest Decrease from 4,880,000 shares to 4,040,000 shares. $TECH https://www.marketbeat.com/stocks/NASDAQ/TECH/shor

cctranscripts Posted - 01/24/24

BlackRock, Inc. just provided an update on share ownership of Techne Corporation https://www.conferencecalltranscripts.org/summary/?id=12890901 $TECH

ChartMill Posted - 01/24/24

$TECH: SCIENTISTS AT THE WCBP CONFERENCE HIGHLIGHT ADVANCEMENTS IN PROTEIN BIOTHERAPEUTIC CHARGE HETEROGENEITY CHARACTERIZATION USING THE MauriceFlex? SYSTEM https://www.chartmill.com/stock/quote/TECH/news?utm_source=prnews-2024-1-24-scientists-at-the-wcbp-conference-highlight-advancements-in-protein-biotherapeutic-charge-heterogeneity-characterization-using-the-mauriceflex-system&utm_medium=stocktwits&utm_campaign=pressRelease

UltraAlgo Posted - 3 months ago

$TECH Sell Rating from 4 signals, 15-min ticks 🚀 Chart by UltraAlgo https://i.redd.it/84259ixm4occ1.png

UltraAlgo Posted - 3 months ago

$TECH Buy Rating based off 6 signals on the 15-minute chart. 💸 Premium Signals at UltraAlgo https://i.redd.it/t0aygvhodhac1.png

PsychedStocks Posted - 3 months ago

$CYBN Phase 1 CYB004 study highlights: -Escalating doses of DMT IV infusion over 90 minutes were well-tolerated- -Robust psychedelic effects were produced, and the intensity of effects was related to the rate at which the peak concentration was achieved.- -Deuteration of DMT, as with CYB004, resulted in stronger psychedelic effects at lower plasma concentrations, compared with native DMT.- -These psychedelic effects were rapid in onset when administered as an IV bolus over 5 minutes and persisted for about 40 minutes after the bolus without the need for an extended infusion.- -This short duration of effects has the potential for CYB004 to be a scalable treatment that can be delivered in a shorter period of time compared with longer acting psychedelics.- https://ir.cybin.com/investors/news/news-details/2024/Cybin-Announces-Positive-Topline-Data-from-Phase-1-Studies-of-Proprietary-Deuterated-DMT-Molecules-CYB004-and-SPL028/default.aspx $BCRX $CROX $TECH $REGN

cctranscripts Posted - 3 months ago

Techne Corporation Releases Unaudited Second Quarter EXHIBIT 99.1 https://www.conferencecalltranscripts.org/summary/?id=12849055 $TECH

Last10K Posted - 3 months ago

$TECH just filed with the SEC a Event for Officers and a Financial Exhibit https://last10k.com/sec-filings/TECH/0001558370-24-000125.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=TECH

Analyst Ratings

Deutsche Bank	Buy	Apr 18, 24
Stephens & Co.	Overweight	Feb 2, 24
RBC Capital	Sector Perform	Feb 2, 24
Stifel	Hold	Feb 2, 24
UBS	Buy	Dec 7, 23
Stifel	Buy	Nov 2, 23
Citigroup	Buy	Nov 1, 23
RBC Capital	Sector Perform	Nov 1, 23
Keybanc	Overweight	Nov 1, 23

Insider Trades	Relationship	Date	Transactions	Cost($)	#Shares	Value($)	#Share Own	SEC Form 4
Kummeth Charles R.	Chief Executive Offi.. Chief Executive Officer	Jul 21	Sell	88.3628	80,000	7,069,024	1,258,766	07/25/23
Kummeth Charles R.	Chief Executive Offi.. Chief Executive Officer	Jun 30	Option	26.65	616,676	16,434,415	1,729,493	07/05/23
Kelderman Kim	Pres. Diagnostics &.. Pres. Diagnostics & Genom	Aug 23	Option	150.78	663	99,967	3,801	08/25/22
Furlow Brenda S.	SVP - General Counse.. SVP - General Counsel	Aug 08	Option	177.32	563	99,831	6,523	08/10/22
Kummeth Charles R.	CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER	Jul 28	Option	108.49	45,346	4,919,588	262,749	08/01/22
Kummeth Charles R.	CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER	Jul 06	Option	108.49	50,000	5,424,500	248,338	07/08/22
HIGGINS JOHN L	Director Director	Jun 07	Option	66.9	1,600	107,040	5,206	06/09/22
HIGGINS JOHN L	Director Director	Jun 07	Sell	365.2	1,600	584,320	4,606	06/09/22
Kummeth Charles R.	CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER	Jun 07	Option	108.49	5,104	553,733	203,442	06/09/22
Kummeth Charles R.	CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER	Jun 07	Sell	365	5,104	1,862,960	198,338	06/09/22
BAUMGARTNER ROBERT V	Director Director	May 10	Buy	352.55	300	105,765	10,106	05/11/22
Hippel James	Chief Financial Offi.. Chief Financial Officer	Nov 01	Option	125.05	9,022	1,128,201	10,955	11/03/21
Hippel James	Chief Financial Offi.. Chief Financial Officer	Nov 01	Sell	526.65	9,022	4,751,436	10,755	11/03/21
Furlow Brenda S.	SVP - General Counse.. SVP - General Counsel	Sep 07	Sell	510.25	6,871	3,505,928	7,620	09/07/21
Furlow Brenda S.	SVP - General Counse.. SVP - General Counsel	Sep 07	Option	125.05	6,871	859,219	14,491	09/07/21
BAUMGARTNER ROBERT V	Director Director	Aug 25	Option	87.39	4,000	349,560	13,612	08/25/21
BAUMGARTNER ROBERT V	Director Director	Aug 25	Sell	485.27	4,000	1,941,080	9,612	08/25/21
Kummeth Charles R.	Chief Executive Offi.. Chief Executive Officer	Jun 16	Sell	449.6	7,481	3,363,458	166,904	06/16/21
Kummeth Charles R.	Chief Executive Offi.. Chief Executive Officer	Feb 18	Option	94.35	30,000	2,830,500	176,269	02/18/21
Eansor Norman David	President-Protein Sc.. President-Protein Sciences	Feb 09	Option	106.59	32,933	3,510,328	34,251	02/09/21
Eansor Norman David	President-Protein Sc.. President-Protein Sciences	Feb 09	Sell	381.75	32,933	12,572,173	1,318	02/09/21
Hippel James	Chief Financial Offi.. Chief Financial Officer	Jan 13	Option	106.59	10,000	1,065,900	19,137	01/13/21
Hippel James	Chief Financial Offi.. Chief Financial Officer	Jan 13	Sell	332.19	10,000	3,321,900	9,137	01/13/21
Furlow Brenda S.	SVP - General Counse.. SVP - General Counsel	Dec 02	Sell	302.1	10,857	3,279,900	6,124	12/02/20
Furlow Brenda S.	SVP - General Counse.. SVP - General Counsel	Dec 02	Option	106.59	11,795	1,257,229	16,981	12/02/20
Hippel James	Chief Financial Offi.. Chief Financial Officer	Nov 12	Option	106.59	10,991	1,171,531	16,528	11/12/20
Hippel James	Chief Financial Offi.. Chief Financial Officer	Nov 12	Sell	309.14	10,991	3,397,758	9,137	11/12/20
Kummeth Charles R.	Chief Executive Offi.. Chief Executive Officer	Nov 10	Option	86.25	25,157	2,169,791	186,644	11/10/20
STEER RANDOLPH C	Director Director	Nov 10	Option	68.63	10,000	686,300	15,112	11/10/20
STEER RANDOLPH C	Director Director	Nov 10	Sell	301.97	10,000	3,019,700	5,112	11/10/20
HIGGINS JOHN L	Director Director	Nov 10	Option	70.35	5,000	351,750	9,412	11/10/20
HIGGINS JOHN L	Director Director	Nov 10	Sell	299.96	5,000	1,499,800	4,412	11/10/20
Hippel James	Chief Financial Offi.. Chief Financial Officer	Nov 06	Option	108.49	15,909	1,725,967	17,946	11/06/20